Evidence map›Paper›PMID 38893215›Full record

ReviewCancers2024

Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review.

Primož Strojan, Marko Kokalj, Gaber Plavc, Sweet Ping Ng, Sandra Nuyts, Carlos M Chiesa-Estomba, Avraham Eisbruch, Remco de Bree, James C H Chow, Antti A Mäkitie and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Primož StrojanDepartment of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0445-112X
Marko KokaljDepartment of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Gaber PlavcDepartment of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-9302-8066
Sweet Ping NgDepartment of Radiation Oncology, Austin Health, The University of Melbourne, Melbourne, VIC 3000, Australia.
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5540-4796
Carlos M Chiesa-EstombaDepartment of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, 20014 San Sebastian, Spain.
Avraham EisbruchDepartment of Radiation Oncology, University of Michigan Medicine, Ann Arbor, MI 48109, USA.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.ORCID 0000-0001-7128-5814
James C H ChowDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, Hong Kong, China.
Antti A MäkitieDepartment of Otorhinolaryngology-Head and Neck Surgery, Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.ORCID 0000-0002-0451-2404
Fernando LopezDepartment of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.ORCID 0000-0001-7019-9746
Nabil F SabaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-4972-1477
Alfio FerlitoCoordinator of the International Head and Neck Scientific Group, 35125 Padua, Italy.ORCID 0000-0002-8247-8002

Funding

Slovenian Research Agency P3-0307
6 · The paper itself

Abstract

Stereotactic body radiotherapy (SBRT) is characterized by a high dose per fraction, well-defined small targets, superior dose conformity, and a steep off-target dose gradient. A literature search was conducted to examine the experience with SBRT as a curative treatment for newly diagnosed mucosal carcinoma of the head and neck (MCHN). Four retrospective case series and one prospective phase I clinical trial published between 2012 and 2020 described 124 patients. SBRT was mainly performed in older patients with different tumor sites. The median size of the planning target volumes ranged from 5.3 to 41 cm

Indexed as

head and neck cancerlocal controlmucosal tumorstereotactic body radiotherapysurvivaltoxicity

Identifiers

PMID38893215
PMCPMC11171035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.